‘An Invisible Profession’: Scarcity Of Quality/Regulatory Experts A Call To Action For Educators

Online-Only Content >>> As baby boomers retire, device manufacturers are scrambling to fill quality and regulatory positions – particularly those in leadership roles, according to an industry survey. Yet many firms are discovering that a number of younger employees – those who typically fill gaps left by retiring managers – have not cultivated the necessary quality and regulatory skills demanded by today's complex global market. "A person going into QA/RA now is not going to be only an expert on United States requirements. Rather, that person has to be educated about global requirements," University of Southern California's Frances Richmond says. The industry survey also noted that a prospective employee's so-called soft skills, such as writing and verbal communication, are deeply valued by manufacturers. Meanwhile, more than 20 universities have banded together to create the Association of Graduate Regulatory Educators to promote QA/RA professions.

FDA's increased emphasis on medical device quality, combined with new and ever-changing regulations from around the world is making it increasingly difficult for manufacturers to find qualified professionals to fill openings in their QA/RA department rosters.

As baby boomers retire, firms are scrambling to fill QA/RA positions – particularly those in leadership roles, according to a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

More from Policy & Regulation

Global Medtech Guidance Tracker: May 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By 

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.